An End-To-End CAR-T Cell Therapy Development Partnership

CAR-T cell therapies are rapidly gaining popularity, with five FDA-approved treatments and hundreds more in development. While these therapies show great promise, ensuring patient safety and treatment effectiveness remains complex. Globally, various groups—from drug discovery and development to manufacturing and clinical laboratories—are turning to Bio-Rad's Droplet Digital PCR (ddPCR) technology. This advanced tool offers a reliable and scalable solution to the numerous workflow challenges faced in the CAR-T cell therapy landscape.